Journal
Transplantation and Cellular Therapy
Publication Date
9-1-2022
Volume
28
Issue
9
First Page
581.e1
Last Page
581.e8
Document Type
Open Access Publication
DOI
10.1016/j.jtct.2022.05.026
Rights and Permissions
Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplant Cell Ther. 2022 Sep;28(9):581.e1-581.e8. doi: 10.1016/j.jtct.2022.05.026. © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Recommended Citation
Jacobson, Caron A; Ghobadi, Armin; and et al., "Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States." Transplantation and Cellular Therapy. 28, 9. 581.e1 - 581.e8. (2022).
https://digitalcommons.wustl.edu/oa_4/1412
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
